Efficacy, safety, and immunogenicity of recombinant insulin aspart (BioGenomics Limited) and NovoRapid® (Novo Nordisk) in adults with type 2 diabetes mellitus: a randomized, open-label, multicenter, phase-3 study

Sneha A. Dongre, Gauri A. Kulkarni, Akshay Mishra, Rutuja B. Deshmane, Nameeta Sonar, Kanica Yashi, Damodar Thapa, Nikhil Ghade, Sachin M. Kadoo , Archana R. Krishnan, Sanjay M. Sonar

Abstract


Background and purpose: To compare the efficacy, safety, and immunogenicity of recombinant insulin aspart 100 U/mL manufactured by BioGenomics Limited (BGL-ASP) with innovator NovoRapid® in type 2 diabetes mellitus patients (T2 DM).

Experimental approach: This was a multicenter, open-label, randomized, parallel-group study in T2 DM patients, on premix human insulin therapy ± oral anti-diabetics. Besides self‐monitored plasma glucose, fasting and post-prandial plasma glucose (FPG and PPG) were tested at baseline, week 12, and week 24. Anti-insulin aspart antibodies measured immunogenicity at 12 and 24 weeks. 

Findings/Results: 160 patients out of 320 patients randomly received BGL-ASP and the remaining patients received NovoRapid®. The changes in glycated hemoglobin (HbA1c) from baseline to weeks 12 and 24 for                       the BGL-ASP group were -0.8 ± 0.83 and -0.8 ± 0.81, respectively, while for the NovoRapid®group was                  -0.8 ± 1.01 and -0.9 ± 0.89, respectively. Changes in FPG and PPG were comparable between the treatment groups after 12 weeks and 24 weeks. The incidence of detectable antibodies at baseline, weeks 12, and 24 were comparable between treatment groups. Eighteen (11.3%) patients in the BGL-ASP group and 23 (14.4%) in the NovoRapid®group reported adverse events.

Conclusion and implications: BGL-ASP and NovoRapid®were comparable and equally effective in lowering HbA1c, FPG, and PPG levels, with similar immunogenicity and safety profiles.

 

 


Keywords


Biosimilar; Immunogenicity; Insulin aspart; NovoRapid®; Type 2 diabetes mellitus.

Full Text:

PDF

References


American Diabetes Association. Standards of medical care in diabetes-2018 abridged for primary care providers. Clin Diabetes. 2018;36(1):14-37.DOI: 10.2337/cd17-0119.

World Health Organization. Global Report on Diabetes. 2016. Available from https://apps.who.int/iris/bitstream/10665/204871/1/9789241565257_eng.pdf.

Mudaliar SR, Lindberg FA, Joyce M, Beerdsen P, Strange P, Lin A, et al. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabetes care. 1999;22(9):1501-1506.DOI: 10.2337/diacare.22.9.1501.

Gao J, Xiong Q, Miao J, Zhang Y, Xia L, Lu M, et al. Analysis of alternatives for insulinizing patients to achieve glycemic control and avoid accompanying risks of hypoglycemia. Biomed Rep. 2015;3(3): 284-288.DOI: 10.3892/br.2015.434.

Lindholm A, Jensen LB, Home PD, Raskin P, Boehm BO, Råstam J. Immune responses to insulinaspart and biphasic insulin aspart in people with type 1 and type 2 diabetes. Diabetes care. 2002;25(5):876-782.DOI: 10.2337/diacare.25.5.876.

Edelman S, Dailey G, Flood T, Kuritzky L, Renda S. A practical approach for implementation of a basal-prandial insulin therapy regimen in patients with type 2 diabetes. Osteopath Med Prim Care. 2007;1(9):1-2.DOI: 10.1186%2F1750-4732-1-9.

Kirchhoff CF, Wang XZM, Conlon HD, Anderson S, Ryan AM, Bose A. Biosimilars: key regulatory considerations and similarity assessment tools. Biotechnol Bioeng. 2017;114(12):2696-2705.DOI: 10.1002/bit.26438.

European Medicines Agency (EMA): guideline on similar biological medicinal products. 2014. Available from http://www.ema.europa.eu/ docs/en_GB/document_library/Scientificguide line/2014/10/WC500176768.pdf. Accessed on 5th May 2023.

US Department of Health and Human Services. US Food and Drug Administration; Center for Drug Evaluation and Research (CDER); Center for Biologics Evaluation and Research (CBER). Scientific considerations in demonstrating biosimilarity to a reference product: guidance for industry. 2015. Available from http://www.fda.gov/ downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm291128.pdf. Accessed on 6th of May 2023.

US Food and Drug Administration. Biosimilarity and Interchangeability: Additional Draft Q&As on Biosimilar Development and the BPCI Act November 2019. Available from https://www.fda.gov/media/133014/download Accessed on 6th of May 2023.

Annex to guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues: guidance on similar medicinal products containing recombinant human soluble insulin (EMEA/CHMP/BMWP/32775/2005). 2006. Available from https://www.ema.europa.eu/ en/documents/scientificguideline/annex-guideline-similar biologic almedicinal-products-containing-biotechnologyderived-proteinsen-0.pdf. Accessed on 7th of May 2023.

Hövelmann U, Raiter Y, Chullikana A, Liu M, Donnelly C, Lawrence T, et al. Pharmacokinetic and pharmacodynamic bioequivalence of biosimilar MYL-1601D with US and European insulin aspart in healthy volunteers: a randomized, double-blind, crossover, euglycaemic glucose clamp study. Diabetes Obes Metab. 2021;23(12):2670-2678.DOI: 10.1111/dom.14519.

Garg SK, Wernicke-Panten K, Wardecki M, Kramer D, Delalande F, Franek E, et al. Efficacy and safety of insulin aspart biosimilar SAR341402 versus originator insulin aspart in people with diabetes treated for 26 weeks with multiple daily injections in combination with insulin glargine: a randomized open-label trial (GEMELLI 1). Diabetes Technol Ther. 2020;22(2):85-95.DOI: 10.1089/dia.2019.0382.

Home P, Derwahl KM, Ziemen M, Wernicke-Panten K, Pierre S, Kirchhein Y, et al. Anti-insulin antibodies and adverse events with biosimilar insulin lispro compared with humalog insulin lispro in people with diabetes. Diabetes Technol Ther. 2018;20(2):160-170.DOI: 10.1089/dia.2017.0373.

Novo Nordisk: NovoLog, insulin aspart injection 100 units/mL, Novo Nordisk. Prescribing information revised: 2021. Available from https://www.novopi.com/novolog.pdf. Accessed on 8th of May 2023.

Blevins TC, Raiter Y, Sun B, Donnelly C, Shapiro R, Chullikana A, et al. Immunogenicity, efficacy, and safety of biosimilar insulin aspart (MYL-1601D) compared with originator insulin aspart (Novolog®) in patients with type 1 diabetes after 24 weeks: a randomized open-label study. BioDrugs. 2022;36(6):761-772.DOI: 10.1007/s40259-022-00554-6.


Refbacks

  • There are currently no refbacks.


Creative Commons LicenseThis work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.